Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity: a case report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sun, Hae Jung | - |
dc.contributor.author | Choi, Kyung Seek | - |
dc.contributor.author | Lee, Sung Jin | - |
dc.date.accessioned | 2021-08-12T02:46:00Z | - |
dc.date.available | 2021-08-12T02:46:00Z | - |
dc.date.issued | 2012-09 | - |
dc.identifier.issn | 0021-5155 | - |
dc.identifier.issn | 1613-2246 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/14872 | - |
dc.description.abstract | Intravitreal injection of bevacizumab in retinopathy of prematurity has shown satisfactory results without any systemic complications. However, increased fibrosis and tissue contraction are reported as adverse effects in some cases. A premature girl, born at 29 weeks + 4 days of gestation, had bilateral aggressive posterior retinopathy of prematurity (APROP) on her first screening at 3 weeks of age. She received extensive, near confluent, laser ablation of the avascular retina and off-label intravitreal bevacizumab (0.75 mg) injection OU. The right eye showed a slight regression, but a localized tractional membrane was noted OS. After another intravitreal bevacizumab injection in each eye, the left eye underwent lens-sparing vitrectomy (LSV) because of contraction of the proliferative membrane leading to a dome-shaped tractional retinal detachment (TRD). At 6-week follow-up, the left eye showed complete retinal reattachment. Both eyes showed prompt resolution of vascular engorgement with anterior progression of the peripheral retinal vasculature. Intravitreal bevacizumab is safe and effective as a treatment of APROP. In some cases tissue contraction may occur, but because TRD is localized to the posterior pole, effective LSV can be performed. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Springer Verlag | - |
dc.title | Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity: a case report | - |
dc.type | Article | - |
dc.publisher.location | 일본 | - |
dc.identifier.doi | 10.1007/s10384-012-0141-8 | - |
dc.identifier.scopusid | 2-s2.0-84866737042 | - |
dc.identifier.wosid | 000308727600010 | - |
dc.identifier.bibliographicCitation | Japanese Journal of Ophthalmology, v.56, no.5, pp 476 - 480 | - |
dc.citation.title | Japanese Journal of Ophthalmology | - |
dc.citation.volume | 56 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 476 | - |
dc.citation.endPage | 480 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Ophthalmology | - |
dc.relation.journalWebOfScienceCategory | Ophthalmology | - |
dc.subject.keywordPlus | PROLIFERATIVE DIABETIC-RETINOPATHY | - |
dc.subject.keywordPlus | RETINAL-DETACHMENT | - |
dc.subject.keywordPlus | ZONE-I | - |
dc.subject.keywordPlus | AVASTIN | - |
dc.subject.keywordPlus | INJECTION | - |
dc.subject.keywordPlus | LASER | - |
dc.subject.keywordAuthor | Anti-VEGF | - |
dc.subject.keywordAuthor | Bevacizumab | - |
dc.subject.keywordAuthor | Lens-sparing vitrectomy | - |
dc.subject.keywordAuthor | Retinopathy of prematurity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.